Replies to post #384893 on Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

Now that I know how you're using the term "definitive" let's go back to the issue that was raised:

"The adverse effect of Heparin was not known at the time the trial was designed."

Are you sure of that?
Besides, last I heard the amount of heparin used wouldn't have had a significant effect.

My "last I heard" was based on two sources.....The CEO's statement, which you consider to be not definitive, and a statistical analysis done by farrell90 which can be found at https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166670757 . The latter seemed thorough...not sure if you would consider it definitive.


"The adverse effect of Heparin was not known at the time the trial was designed."

"Given heparin is dosed at such low concentrations, we wouldnt anticipate any large effect of Heparin on Brilacidin's blocking property in the COVID trial."
Did the CEO reach that conclusion before the trial design was finalized or did he not know that it needed to be considered?
It's hard to see it both ways. If he didn't know of the possibility of an adverse effect of Heparin before the trial was designed he should have, shouldn't he? Or he did know, considered it to be negligible, and you're mistaken in your statement. Pick one.

Furthermore we'd have to believe that no one saw fit to do the farrell90 analysis prior to the design of the trial if your statement about the adverse effect of Heparin not being known before the trial was designed to be accepted.

Please consider the above.

I expect you found the paper reference less compelling given that you left it unaddressed.
I believe the heparin issue was known to Scott and Degrado in 2014 based on my amateurish interpretation of the paper that they authored (with others). You didn't address that possibility and I can't blame you for that....I didn't offer it as definitive proof, but it seemed to me to be at least suggestive of SOME KNOWLEDGE of the issue by CTIX closely related parties.
"De novo design of self-assembling foldamers that inhibit heparin-protein interactions"
https://pubmed.ncbi.nlm.nih.gov/24491145/


Bottom line?
The "heparin effect" would only matter to the extent that it affected the trial results and the CEO and farrell90 both seem to think that it couldn't have. I hope they're right.